- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03753061
Intracranial Thrombosis Aspiration Catheter for Recanalization in Acute Ischemic Stroke Therapy (RECOVER)
The Safety and Efficacy of Intracranial Thrombosis Aspiration Catheter for Recanalization in Acute Ischemic Stroke Therapy- A Prospective, Multicenter, Open Label, Blinded, Randomized Controlled, Non-inferiority Study
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a prospective, multi-center, open-label, end-point blinded, parallel positive controlled, non-inferiority clinical trial. Patients with acute ischemic stroke (AIS) who meet inclusion criteria would be enrolled in this study. Led by Beijing Tiantan Hospital affiliated to Capital Medical University, this study is planned to be carried out in 15-20 clinical trial institutions in China. There will be 102 patients enrolled in each group. Patients in the experimental group will be treated with the intracranial thrombus aspiration catheter, product of Hemo Jirui. Patients in the control group will be treated with stent retriever (Solitaire FR).
In this trial, relevant examinations of safety and efficacy assessments were performed immediately after the procedure, at 24 hours, 7 days, 30 days, and 90 days. Primary efficacy endpoint will be the immediate recanalization rate (mTICI 2b-3) of target vessel after the procedure. Secondary efficacy endpoints will include: (1) Proportion of functional independence (mRS 0-2) at 90 days; (2) ordinal shift analysis of mRS at 90 days; (3) immediate recanalization rate (mTICI 2b-3) of the first pass of thrombectomy device; (4) immediate recanalization rate (mTICI 2b-3) of the last pass of thrombectomy device; (5)procedure time (randomization to recanalization); (6) Change in NIHSS score at 24hours; (7) Change in NIHSS score at 7 days or discharge (whichever comes first); (8) mTICI grading of target vessel revealed by CTA or MRA at 22-36 hours; (9) The extent of anterior circulation infarction at 22-36 hours, as measured by ASPECTS on CT or MRI. Safety endpoints will include: (1) All-cause mortality at 90 days; (2) stroke-related mortality at 90 days; (3) stroke recurrence rate within 90 days; (4) any type of intracranial hemorrhagic transformation within 22-36 hours, including parenchymal, subarachnoid or ventricular hemorrhage; (5) symptomatic intracranial hemorrhage (sICH) within 22-36 hours, as confirmed by any intracranial hemorrhage on CT or MRI associated with ≥ 4 points of worsening on NIHSS or even contributing to death; (5) procedural complications or serious adverse events procedural complications or serious adverse events (SAEs) within 90 days.
The trial is anticipated to last from November 2018 to May 2019, all the related investigative organization and individuals will obey the Declaration of Helsinki and Chinese Good Clinical Practice standard. The trial has been approved by Institutional Review Board (IRB) and Ethics Committee(EC) in Being Tiantan hospital, Capital Medical University.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhongrong Miao, MD
- Phone Number: 86-010-67098857
- Email: 13601243293@163.com
Study Contact Backup
- Name: Yan Lin, Master
- Phone Number: 86-13911573513
- Email: yan.lin@hemochina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital, Capital Medical University
-
Principal Investigator:
- Zhongrong Miao, MD
-
Contact:
- Zhongrong Miao, MD
-
Beijing, Beijing, China, 100000
- Recruiting
- Beijing Friendship Hospital, Capital Medical University
-
Contact:
- Quanshan Ai
-
Principal Investigator:
- Quanshan Ai
-
Beijing, Beijing, China, 100000
- Recruiting
- Beijing Luhe Hospital Medical University
-
Contact:
- Xiaokun Geng
-
Principal Investigator:
- Xiaokun Geng
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- The Second Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Zhou Xing
-
Principal Investigator:
- Zhou Xing
-
Principal Investigator:
- Xinguang Yang
-
-
Hebei
-
Baoding, Hebei, China, 071000
- Recruiting
- Affiliated Hospital of Hebei University
-
Contact:
- Zhiqiang Li
-
Principal Investigator:
- Zhiqiang Li
-
Tangshan, Hebei, China, 063000
- Recruiting
- Tangshan People's Hospital
-
Contact:
- Yan Wang
-
-
Henan
-
Luoyang, Henan, China, 471000
- Recruiting
- Luoyang Central Hospital
-
Contact:
- Liping Wei
-
Zhengzhou, Henan, China, 450000
- Recruiting
- The first affiliated hospital of Zhengzhou University
-
Contact:
- Sheng Guan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Henan province people's hospital
-
Contact:
- Tianxiao Li
-
Principal Investigator:
- Tianxiao Li
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Zhengzhou Central Hospital
-
Principal Investigator:
- Haibo Wang
-
-
Hubei
-
Shiyan, Hubei, China, 442000
- Recruiting
- Taihe Hospital
-
Contact:
- Zhibing Ai
-
Principal Investigator:
- Zhibing Ai
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- The Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Xinchun Ye
-
Principal Investigator:
- Xinchun Ye
-
-
Neimenggu
-
Baotou, Neimenggu, China, 014000
- Recruiting
- Baotou Central Hospital
-
Principal Investigator:
- Changchun Jiang
-
Contact:
- Changchun Jiang
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Recruiting
- Tangdu Hospital
-
Contact:
- Zhenwei Zhao
-
Principal Investigator:
- Zhenwei Zhao
-
Xi'an, Shaanxi, China, 710000
- Recruiting
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Principal Investigator:
- Jianfeng Han
-
Contact:
- Jianfeng Han
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Recruiting
- Qilu Hospital of Shandong University
-
Principal Investigator:
- Wei Wu
-
Liaocheng, Shandong, China, 252000
- Recruiting
- Liaocheng People's Hospital
-
Contact:
- Liyong Zhang
-
Principal Investigator:
- Liyong Zhang
-
Qingdao, Shandong, China, 266000
- Recruiting
- Qingdao Central Hospital
-
Contact:
- Haicheng Yuan
-
Principal Investigator:
- Haicheng Yuan
-
Weihai, Shandong, China, 264400
- Recruiting
- Weihai Central Hospital
-
Contact:
- Hongjun Hou
-
Principal Investigator:
- Hongjun Hou
-
Yantai, Shandong, China, 264000
- Recruiting
- Yantaishan Hospital
-
Contact:
- Dianjing Sun
-
Principal Investigator:
- Dianjing Sun
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- Recruiting
- First Hospital Of ShanXi Medical University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Tianjin Medical University General Hospital
-
Contact:
- Li Yang
-
Tianjin, Tianjin, China, 300000
- Recruiting
- Tianjin First Central Hospital
-
Contact:
- Binge Chang
-
Principal Investigator:
- Binge Chang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years.
- Symptoms and signs in accordance with anterior circulation ischemia and large vessel occlusion (ICA, MCA-M1 or M2) confirmed by CTA/MRA/DSA.
- Pre-stroke Modified Rankin Scale(mRS)0-1.
- NIHSS score ≥ 6 points at time of randomization.
- The patients should receive endovascular treatment within 8 hours of estimated time of large vessel occlusion (LVO) onset, and have an ASPECTS ≥ 6 points on non-enhanced CT.
- If intravenous thrombolysis with tPA (IVT) is considered as part of standard medical management, IVT should be started within 4.5 hours of estimated time of LVO. Furthermore, in AIS patients with an unknown time of onset, IVT guided by a mismatch between DWI and FLAIR in the region of ischemia is also recommended.
- Written informed consent obtained from patient or patient's legally authorized representative.
Exclusion Criteria:
- Acute posterior circulation cerebral infarction comfirmed by CT or MRI.
- Any type of cerebral hemorrhage (only microbleeds are allowed) on neuroimaging.
- Large (more than one-third of the MCA) regions of clear hypodensity on the baseline CT scan or ASPECTS < 7 points or significant mass effect with midline shift.
- Proven occlusion of the common carotid artery.
- Known or suspected chronic occlusion of target vessel.
- Known life threatening allergy (more than rash) to iodinated contrast agent.
- Arterial tortuosity and other problems that would prevent the device from reaching the target vessel.
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency.
- Baseline platelet count < 50000/µL.
- Severe heart, liver or kidney failure and other serious or terminal illness.
- Major surgery within the past 2 weeks
- Haemorrhage of the gastrointestinal or urinary tract within the past 3 weeks.
- Baseline blood glucose < 2.7 or > 22.2 mmol/L.
- Baseline blood pressure > 185/110 mmHg, or aggressive treatment (intravenous medication) necessary to reduce blood pressure to these limits
- Pregnant or lactating or positive pregnancy test on admission.
- Dementia or psychiatric disease that would confound the neurological or functional evaluations.
- Life expectancy less than 1 year.
- Current participation in another drug or device research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aspiration Catheter
Mechanical thrombectomy with Aspiration Catheter.
|
Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
|
Active Comparator: Stent Retriever (Solitaire FR)
Mechanical thrombectomy with Solitaire FR.
|
Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Instant recanalization rate (mTICI 2b-3) of target vessel after the procedure
Time Frame: immediate
|
immediate
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of functional independence (mRS 0-2) at 90 days
Time Frame: 90 days
|
90 days
|
Ordinal shift analysis of mRS at 90 days
Time Frame: 90 days
|
90 days
|
Instant recanalization rate (mTICI 2b-3) after the first thrombectomy
Time Frame: immediate
|
immediate
|
Instant recanalization rate (mTICI 2b-3) after the last thrombectomy
Time Frame: immediate
|
immediate
|
Procedure time (randomization to recanalization)
Time Frame: procedure
|
procedure
|
Change in NIHSS score at 24±2 hours
Time Frame: 24 hours
|
24 hours
|
Change in NIHSS score at 7±1 days or discharge (whichever comes first)
Time Frame: 7 days
|
7 days
|
mTICI grading of target vessel revealed by CTA or MRA at 22-36 hours
Time Frame: 22-36 hours
|
22-36 hours
|
The extent of anterior circulation infarction at 22-36 hours, as measured by ASPECTS on CT or MRI
Time Frame: 22-36 hours
|
22-36 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Embolism and Thrombosis
- Brain Ischemia
- Infarction
- Brain Infarction
- Intracranial Embolism and Thrombosis
- Thromboembolism
- Stroke
- Ischemic Stroke
- Ischemia
- Thrombosis
- Cerebral Infarction
- Cerebrovascular Disorders
- Intracranial Thrombosis
Other Study ID Numbers
- HEMO-CS1802
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrovascular Disorders
-
Peking University Third HospitalBeijing HospitalCompletedCerebrovascular DiseasesChina
-
University Health Network, TorontoEisai Inc.CompletedDementia Associated With Cerebrovascular DiseaseCanada
-
Eisai Co., Ltd.CompletedA Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular DiseaseDementia Associated With Cerebrovascular DiseaseKorea, Republic of
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown
-
First Affiliated Hospital of Harbin Medical UniversityRecruitingCerebrovascular Disease Small VesselChina
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownCerebrovascular AccidentsTaiwan
-
Chinese PLA General HospitalNot yet recruitingCardiovascular and Cerebrovascular Diseases
-
University of Alabama at BirminghamCompleted
-
MyomoUnknownCerebrovascular AccidentsUnited States
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanCompleted
Clinical Trials on Solitaire FR
-
Universität des SaarlandesCompletedAcute StrokeGermany
-
Jinling Hospital, ChinaCompleted
-
Ministry of Science and Technology of the People´s...CompletedAcute Ischemic StrokeChina
-
Medtronic Neurovascular Clinical Affairsev3 InternationalCompleted
-
Suzhou Zenith Vascular Scitech Co., Ltd.CompletedAcute Ischemic Stroke | Large Vessel Occlusion | AIS | ThrombectomyChina
-
Fundacio Ictus Malaltia VascularMedtronic - MITGTerminated
-
Xuanwu Hospital, BeijingRecruitingStroke | Acute Ischemic StrokeChina
-
Gregory W AlbersMedical University of South Carolina; National Institute of Neurological Disorders... and other collaboratorsTerminatedCerebral Infarction | Stroke, AcuteUnited States
-
Hospital de Clinicas de Porto AlegreMinistry of Health, Brazil; Medtronic; Penumbra Inc.; Brainomix Limited; iSchemaView...Completed
-
University of LouisvilleCompleted